Kiniksa Pharmaceuticals International, plc KNSA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's cash & equivalents?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported cash & equivalents of $189.95M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's cash & equivalents changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's cash & equivalents increased by 20.9% year-over-year, from $157.13M to $189.95M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's cash & equivalents?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $114.04M to $165.6M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.